Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 22, 2022 - Issue 1
Submit an article Journal homepage
1,769
Views
2
CrossRef citations to date
0
Altmetric
Letter To The Editor

Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

Raquel Rivera-Díaza Dermatology Service, Universitary Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4604-0724View further author information
ORCID Icon,
Mar LLamas-Velascob Dermatology Service, Universitary Hospital La Princesa, Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-1187-1341View further author information
ORCID Icon,
Mercedes Hospitalc Dermatology Service, Universitary Hospital Puerta de Hierro Majadahonda, Madrid, SpainView further author information
,
Isabel Martínd Dermatology Service, Universitary Hospital de Getafe, Madrid, SpainView further author information
,
Ofelia Baniandrése Dermatology Service, Universitary Hospital Gregorio Marañón, Madrid, SpainView further author information
,
Diana Ruíz-Genaof Dermatology Service, Universitary Hospital Fundación Alcorcón, Madrid, SpainView further author information
,
Pablo de la Cuevag Dermatology Service, Universitary Hospital Infanta Leonor, Madrid, SpainView further author information
&
Carmen García-Donosoa Dermatology Service, Universitary Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, SpainView further author information
 show all
Pages 105-107 | Received 29 Oct 2021, Accepted 26 Nov 2021, Published online: 12 Dec 2021

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Angelo Ruggiero, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini & Matteo Megna. (2022) Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clinical, Cosmetic and Investigational Dermatology 15, pages 1649-1658.
Read now

Articles from other publishers (1)

Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela & Gabriella Fabbrocini. (2022) Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study. Dermatologic Therapy 35:7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.